AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN240)
The Pharma Data
JULY 29, 2021
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . United States and virtually from July 26 to 30, 2021 (Presentation No.:
Let's personalize your content